F605 in Delaware. Pick another state for the same tag.
Against expectation — 2025
Delaware cites F605 less often than its own record predicts
Versus expected share0.30×
0.30 times the national share — cited less often here than elsewhere.
Share of Delaware citations0.21%
Of every deficiency written in Delaware in 2025, this is the portion that was F605.
Delaware0.21%
National0.70%
Share of all citations that were F605.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Delaware surveyors wrote
F605 findings written in Delaware, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
D · No harm, potential for more than minimal, isolatedJuly 30, 2026
Based on record review and interview it was determined that for one (R17) out of two residents reviewed for behavioral/emotional condition the facility failed to ensure adequate monitoring of antipsychotic medication use. Findings include: Review of R17's clinical record revealed: 12/22/23 - R17 was admitted to the facility with multiple diagnoses including anxiety, schizophrenia, and depression. 6/25/25 - An AIM's assessment documented R17 as a 0.0 score indicating no side effects from use of antipsychotic medications. 9/17/25 - An AIM's assessment documented R17 as a 4.0 score indicating the presence side effects from use of antipsychotic medications. 11/19/25 - A psychiatric evaluation and consultation was completed for R17. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction